Shares of Moderna MRNA rose nearly 6% yesterday after the U.S. Centers for Disease Control and Prevention (“CDC”) adopted new ...

The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

An mRNA-based flu vaccine has the potential advantage to more precisely match circulating strains, support rapid response in a future influenza pandemic, and pave the way for COVID-19 combination ...

The US Food and Drug Administration’s top vaccine official overrode agency experts in May to recommend against the broad use ...

If we don’t invest in technologies like mRNA vaccines for pandemic influenza now, once a virus starts going human-to-human, ...

The Food and Drug Administration has approved three vaccines for RSV — GSK's GSK.L Arexvy, Moderna's MRNA.O mRESVIA and ...

The Trump administration is eroding national pandemic flu defenses as it guts health agencies, cuts research and health ...

Records show that a top U.S. regulator rejected the recommendations of agency experts and limited the use of Covid vaccines.

The promise of mRNA technology seemed boundless after the success of the coronavirus vaccines, but Robert F. Kennedy Jr. has singled it out for scrutiny, clouding its prospects.

Chronic heart failure and hypoalbuminaemia are linked to a poor antibody response at 3 months after the third dose of the ...